POLA PENGGUNAAN OBAT ANTIDIABETES PADA PASIEN JAMINAN KESEHATAN NASIONAL RAWAT JALAN DI RUMAH SAKIT UMUM DAERAH KOTA MATARAM TAHUN 2023
DOI:
https://doi.org/10.66294/njms.v2i11.148Keywords:
diabetes mellitus, antidiabetic drugs, national health insurance, rational drug useAbstract
Diabetes mellitus is a chronic disease characterized by metabolic disorders of carbohydrates, fats, and proteins due to insulin deficiency or resistance. The increasing prevalence of diabetes in Indonesia requires rational drug use, especially among National Health Insurance (JKN) patients. This study aims to determine the pattern of antidiabetic drug use in outpatients at Mataram City Regional General Hospital in 2023. This research used a descriptive method with a retrospective approach based on prescription data of JKN patients. The results showed that the most commonly used therapy was a combination of oral antidiabetic drugs, with metformin as the primary treatment. The use of combination therapy indicates efforts to optimize glycemic control. However, variations in drug use were still found, which may affect treatment effectiveness. In conclusion, the pattern of antidiabetic drug use among JKN outpatients in 2023 tends toward rational therapy but still requires continuous evaluation to improve healthcare quality.
Downloads
References
American Diabetes Association. (2023). Standards of Medical Care in Diabetes—2023. Diabetes Care, 46(Supplement 1), S1–S291.
Arikunto, S. (2019). Prosedur Penelitian Suatu Pendekatan Praktik. Jakarta: Rineka Cipta. Katzung, B. G. (2018). Basic and Clinical Pharmacology. New York: McGraw-Hill.
Badan Penelitian dan Pengembangan Kesehatan. (2019). Laporan Riskesdas 2018. Jakarta: Kementerian Kesehatan RI.
BPJS Kesehatan. (2023). Panduan Praktis Pelayanan Kesehatan. Jakarta: BPJS Kesehatan.
BPOM RI. (2021). Informatorium Obat Nasional Indonesia (IONI). Jakarta: Badan POM.
Davies, M. J., et al. (2018). Management of hyperglycemia in type 2 diabetes. Diabetes Care, 41(12), 2669–2701.
Departemen Kesehatan Republik Indonesia. (2020). Pedoman Penggunaan Obat Rasional. Jakarta: Depkes RI.
Dipiro, J. T., Talbert, R. L., Yee, G. C., Matzke, G. R., Wells, B. G., & Posey, L. M. (2020). Pharmacotherapy: A Pathophysiologic Approach (11th ed.). New York: McGraw-Hill Education.
Goodman, L. S., & Gilman, A. (2018). The Pharmacological Basis of Therapeutics (13th ed.). New York: McGraw-Hill.
Inzucchi, S. E., et al. (2015). Management of hyperglycemia in type 2 diabetes. Diabetes Care, 38(1), 140–149.
International Diabetes Federation. (2021). IDF Diabetes Atlas (10th ed.). Brussels: IDF.
Katzung, B. G. (2018). Basic and Clinical Pharmacology. New York: McGraw-Hill.
Kementerian Kesehatan Republik Indonesia. (2023). Profil Kesehatan Indonesia Tahun 2022. Jakarta: Kemenkes RI.
Kementerian Kesehatan Republik Indonesia. (2020). Formularium Nasional. Jakarta: Kemenkes RI.
Nathan, D. M. (2015). Diabetes: Advances in diagnosis and treatment. JAMA, 314(10), 1052–1062.
Notoatmodjo, S. (2018). Metodologi Penelitian Kesehatan. Jakarta: Rineka Cipta.
Perkumpulan Endokrinologi Indonesia (PERKENI). (2021). Pedoman Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia. Jakarta: PERKENI.
Riddle, M. C., & Herman, W. H. (2018). The cost of diabetes care—An elephant in the room. Diabetes Care, 41(5), 929–932.
Riset Kesehatan Dasar. (2018). Hasil Utama Riskesdas. Jakarta: Kemenkes RI.
Sugiyono. (2019). Metode Penelitian Kuantitatif, Kualitatif dan R&D. Bandung: Alfabeta.
Triplitt, C. L., Reasner, C. A., & Isley, W. L. (2019). Diabetes Mellitus. In Pharmacotherapy Handbook.
Wells, B. G., et al. (2020). Pharmacotherapy Principles and Practice. New York: McGraw-Hill.
World Health Organization. (2022). Global Report on Diabetes. Geneva: WHO.
World Health Organization. (2023). Guidelines on Diabetes Management. Geneva: WHO.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Annisaturrahmah Himawan
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
NJMS is licensed under a Creative Commons Attribution-Attribution-ShareAlike 4.0 International License.
Articles in this journal are Open Access articles published under the Creative Commons CC BY-SA License This license permits use, distribution and reproduction in any medium for non-commercial purposes only, provided the original work and source is properly cited. Any derivative of the original must be distributed under the same license as the original.
